glp-1-coverage-appeals">UnitedHealthcare Diabetes Supplies Denied: CGM, Insulin Pumps, and GLP-1 Coverage Appeals

Diabetes management has been transformed by continuous glucose monitors (CGMs), insulin pumps, and GLP-1 receptor agonists. But UnitedHealthcare's coverage policies for these technologies have not always kept pace with clinical evidence. If UHC denied your CGM device, insulin pump, or GLP-1 prescription, you have strong grounds to appeal — and understanding UHC's specific criteria is the first step.

Continuous Glucose Monitor (CGM) Denials

Dexcom and Abbott FreeStyle Libre are the two dominant CGM brands, and both are the subject of frequent UHC Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization battles. UHC's coverage criteria for CGMs have evolved significantly, but common denial reasons include:

• Not insulin-dependent: UHC has historically required insulin-dependent diabetes (Type 1, or Type 2 on insulin) for CGM coverage. Members managing diabetes with oral medications alone have faced denials even when clinical evidence supports CGM use for glycemic control improvement.
• Insufficient A1C documentation: UHC may require that A1C is above a certain threshold or that the member has a documented history of hypoglycemic episodes
• Wrong formulary classification: CGMs may be covered under the pharmacy benefit, the durable medical equipment (DME) benefit, or both, depending on plan design. If submitted under the wrong benefit, it may be denied

For CGM appeals, your endocrinologist's letter should document: your diabetes diagnosis and treatment history, your A1C and glucose variability, any history of hypoglycemic events, and the clinical rationale for CGM use in your specific management plan. Cite the American Diabetes Association's Standards of Care, which support CGM use broadly for patients with diabetes on insulin and increasingly for those not on insulin.

Insulin Pump Denials

Insulin pump (continuous subcutaneous insulin infusion or CSII) denials from UHC are common and often frustrating because pumps are well-established standard of care for Type 1 diabetes. UHC's coverage criteria for insulin pumps typically require:

• Documentation of Type 1 diabetes or Type 2 diabetes requiring multiple daily insulin injections
• Demonstrated failure of or inadequacy with multiple daily injection therapy
• Patient must be capable of managing the device (or have a caregiver who can)
• Physician experienced in pump therapy who will supervise the patient's treatment

If UHC denied your insulin pump, the appeal should include: your endocrinologist's Letter of Medical Necessity documenting your A1C history, hypoglycemic episodes, and why pump therapy is clinically superior to MDI for your management; documentation of your prior MDI regimen and its inadequacy; and evidence that you have been trained or will be trained on pump use.

GLP-1 Receptor Agonist Formulary Issues

GLP-1 medications — including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) — have become among the most contested drugs in pharmacy benefit management. UHC's OptumRx formulary places GLP-1 medications on high tiers or subjects them to prior authorization with step therapy requirements.

Common GLP-1 denial scenarios with UHC include:

• Ozempic for Type 2 diabetes: Required to try metformin and at least one other oral agent first (step therapy)
• Wegovy/Zepbound for obesity: Often excluded from employer plan pharmacy benefits unless the employer specifically opted in to obesity drug coverage; UHC does not include these in its standard formulary
• Brand vs. generic: UHC may require generic alternatives where available, though most GLP-1s have no generics currently

For GLP-1 step therapy denials, document your treatment history with prior medications, including why they were inadequate or contraindicated. The American Diabetes Association and the Obesity Medicine Association have published strong guidance supporting GLP-1 use that your physician can cite.

Formulary Exception Process

If your diabetes medication is not on UHC's OptumRx formulary or is on a tier that makes it unaffordable, you can request a formulary exception. To qualify, your prescribing physician must document:

• Medical reason why a lower-tier alternative is not appropriate for you
• Any adverse effects or contraindications to formulary alternatives
• Clinical need for the specific drug requested

Submit formulary exception requests through OptumRx or UHC's member portal. These requests can be submitted by your physician on your behalf.

How to File a UHC Diabetes Supply Appeal

1. Request the full denial reason and the specific coverage criteria UHC applied
2. Obtain a detailed Letter of Medical Necessity from your endocrinologist
3. Gather your relevant lab results: A1C history, CGM download data showing glucose patterns, hypoglycemia log
4. File the Level 1 internal appeal within your denial deadline, citing ADA Standards of Care
5. If denied again, request External Independent Review: Complete Guide" class="auto-link">external review through UHC or your state insurance department

Call UHC at 1-800-721-4095 or use myuhc.com for appeals. For OptumRx pharmacy issues, call the OptumRx member line listed on your pharmacy card.

Fight Back With ClaimBack

Diabetes supply and medication denials by UHC are frequently based on outdated criteria that do not reflect current ADA guidelines. ClaimBack helps you build an appeal that directly addresses UHC's specific denial criteria for CGMs, pumps, and GLP-1s.

Start your UHC diabetes supplies appeal with ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied